Swiss National Bank recently reduced its holding in Rhythm Pharmaceuticals by a modest 900 shares during the first quarter, as disclosed in a new SEC filing. Despite the small adjustment, the bank retains a significant position in the company.

Rhythm Pharmaceuticals announces promising results from their Phase 3 TRANSCEND trial, where setmelanotide significantly reduced BMI in patients with acquired hypothalamic obesity. This breakthrough offers new hope for treating this rare condition resulting from hypothalamic damage.